Top
Begin typing your search above and press return to search.
exit_to_app
Keralas KIIFB and the Centre
access_time 2021-03-05T11:40:28+05:30
access_time 2021-03-04T11:13:32+05:30
The struggle to retrieve the kitchen
access_time 2021-03-03T11:31:58+05:30
Disgruntled dissidents and future of Congress
access_time 2021-03-02T11:58:48+05:30
access_time 2021-03-01T15:37:17+05:30
DEEP READ
Towards a digital emergency?
access_time 2021-02-27T14:50:41+05:30
The slaughter of democracy in Puducherry
access_time 2021-02-24T11:27:21+05:30
Populist Fascism
access_time 2021-01-31T17:19:29+05:30
Media Freedom
access_time 2021-01-31T15:47:07+05:30
Sharjeel Imam
access_time 2021-01-30T15:19:40+05:30
exit_to_app
Homechevron_rightIndiachevron_rightCovid Vaccine: SII...

Covid Vaccine: SII instructed to prioritise India, CEO urges others to be patient

text_fields
bookmark_border
Covid Vaccine: SII instructed to prioritise India, CEO urges others to be patient
cancel

Adar Poonawalla, CEO of the Serum Institute of India, requested countries and governments awaiting the Covishield vaccine to "please be patient" as the institute has been directed to put the needs of the country ahead of export. Serum Institute of India is the world's largest vaccine manufacturer and is developing the covid vaccine Covishield in partnership with Oxford University and AstraZeneca.

"Dear countries & governments, as you await #COVISHIELD supplies, I humbly request you to please be patient, @SerumInstIndia has been directed to prioritise the huge needs of India and, along with that, balance the needs of the rest of the world. We are trying our best," Poonawalla tweeted.

Covishield has been producing vaccines for export to about 25 countries, including Brazil, Mexico and Canada, while also trying to cater to domestic needs. Covishield and Covaxin are the two vaccines cleared by the DCGI for administration in the country.

Show Full Article
TAGS:Covid 19 vaccine Covid19 updates 
Next Story